We were fortunate to have the opportunity to catch up with European editorial board member, Heinz Reichmann (Universitätsklinikum Carl Gustav Carus, Dresden, Germany), who spoke to us about unmet needs in the treatment of Parkinson’s disease and clinical evidence supporting the efficacy and safety of catechol-O-methyltransferase inhibition as a means to prolong the effects of levodopa.
Questions
1. What are the major unmet needs in the treatment of Parkinson’s disease? (0:05)
2. Could you tell us a little about opicapone and the clinical evidence supporting its efficacy and safety? (1:24)
Also see linked video: Heinz Reichmann, EAN 2020 – OPTIPARK Study in Patients with Parkinson’s and Motor Fluctuations
Speaker disclosure: Heinz Reichmann reports having received honoraria from Bial for his participation in advisory board meetings and satellite symposia.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.
